

September 21, 2010



Kane Biotech Develops DispersinB(R) Monoclonal Antibodies

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 09/21/10 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce that the development and selection of hybridoma cell lines to produce anti-DispersinB® monoclonal antibodies for a DispersinB® immunoassay has been successfully completed.

DispersinB® is a very active enzyme used in micro quantities. The development of a specific and sensitive monoclonal antibody-based immunoassay method for detection and quantification of DispersinB® in nanograms or micrograms is essential in the product's development. The successful cloning and selection of stable hybridoma cell lines producing an optimal antibody titer is an important step in the development of a DispersinB® enzyme-linked immunosorbent assay (ELISA) kit.

"The DispersinB®-specific ELISA kit will be very useful in studying the release kinetics of DispersinB® enzyme in medical devices and wound care products eluting trace amounts of enzyme," stated Dr. Sri Madhyastha, Vice President-Research and Chief Scientific Officer of Kane Biotech. "Additionally, this kit will be helpful in measuring the concentrations of DispersinB® in nanograms during the enzyme's production by E. coli fermentation."

"This DispersinB® ELISA kit will be complimentary to the current testing of our DispersinB® technology by a number of companies, universities and research institutes all over the world," stated Gord Froehlich, President and CEO of Kane Biotech. "With the development of DispersinB® monoclonal antibodies completed, we will now move forward to completing development of the ELISA kit."

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as medical device and wound associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the

ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts:

Kane Biotech Inc.

Gord Froehlich

President & Chief Executive Officer

204-477-7592

204-453-1314 (FAX)

ir@kanebiotech.com

www.kanebiotech.com

